Hajime Osawa1, Toshihiro Shiozawa1, Shinichiro Okauchi2, Kunihiko Miyazaki3, Takahide Kodama3, Katsunori Kagohashi2, Ryota Nakamura4, Hiroaki Satoh5, Nobuyuki Hizawa1. 1. Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan 2. Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba–Mito Kyodo General Hospital, Mito, Japan 3. Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan 4. Division of Surgery, National Hospital Organization Mito Medical Center, Mito, Japan 5. Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba–Mito Kyodo General Hospital, Mito, Japan. hirosato@md.tsukuba.ac.jp
Abstract
Introduction: There is an unmet clinical need to identify biomarkers predicting which patients with non–small cell lung cancer (NSCLC) would benefit from treatment with immune checkpoint inhibitors (ICPIs). Objectives: The purpose of this study was to draw a detailed time to treatment failure (TTF) curve with information on the changes in peripheral eosinophil expression during ICPI treatment for NSCLC, and to clarify whether eosinophil expression can predict prolonged TTF. Patients and methods: In 259 patients with NSCLC treated with ICPI therapy, peripheral eosinophil counts and percentages at the time of each ICPI administration were evaluated from the beginning of ICPI treatment up to TTF. Univariable and multivariable analyses were performed to identify clinical factors associated with TTF. Results: Patients receiving ICPI monotherapy (n = 180) were divided into 3 groups (TTF ≤6 weeks, TTF >6 weeks and ≤24 weeks, and TTF >24 weeks) and the number of patients with an eosinophil percentage of 5% or more within 6 weeks of ICPI therapy initiation was significantly different among these groups. In univariable and multivariable analyses, performance status of 0 to 1, immune-related adverse event not requiring ICPI discontinuation as well as an eosinophil percentage of 5% or more and an eosinophil count of 330/μ or more within 6 weeks of ICPI therapy initiation were significant favorable factors for prolonged TTF. In patients treated with combination therapy of ICPI and chemotherapy (n = 79), the number of patients with an eosinophil percentage of 5% or more within 12 weeks of therapy initiation was significantly different between patients with a TTF of up to 12 weeks and those with a more prolonged TTF. However, the only significant favorable factor for TTF was female sex. Conclusions: In NSCLC patients treated with ICPI therapy, particularly ICPI monotherapy, eosinophil measurements during treatment might be useful for predicting prolonged TTF.
Introduction: There is an unmet clinical need to identify biomarkers predicting which patients with non–small cell lung cancer (NSCLC) would benefit from treatment with immune checkpoint inhibitors (ICPIs). Objectives: The purpose of this study was to draw a detailed time to treatment failure (TTF) curve with information on the changes in peripheral eosinophil expression during ICPI treatment for NSCLC, and to clarify whether eosinophil expression can predict prolonged TTF. Patients and methods: In 259 patients with NSCLC treated with ICPI therapy, peripheral eosinophil counts and percentages at the time of each ICPI administration were evaluated from the beginning of ICPI treatment up to TTF. Univariable and multivariable analyses were performed to identify clinical factors associated with TTF. Results: Patients receiving ICPI monotherapy (n = 180) were divided into 3 groups (TTF ≤6 weeks, TTF >6 weeks and ≤24 weeks, and TTF >24 weeks) and the number of patients with an eosinophil percentage of 5% or more within 6 weeks of ICPI therapy initiation was significantly different among these groups. In univariable and multivariable analyses, performance status of 0 to 1, immune-related adverse event not requiring ICPI discontinuation as well as an eosinophil percentage of 5% or more and an eosinophil count of 330/μ or more within 6 weeks of ICPI therapy initiation were significant favorable factors for prolonged TTF. In patients treated with combination therapy of ICPI and chemotherapy (n = 79), the number of patients with an eosinophil percentage of 5% or more within 12 weeks of therapy initiation was significantly different between patients with a TTF of up to 12 weeks and those with a more prolonged TTF. However, the only significant favorable factor for TTF was female sex. Conclusions: In NSCLC patients treated with ICPI therapy, particularly ICPI monotherapy, eosinophil measurements during treatment might be useful for predicting prolonged TTF.
Authors: Yu-Wei Chen; Matthew D Tucker; Landon C Brown; Hesham A Yasin; Kristin K Ancell; Andrew J Armstrong; Kathryn E Beckermann; Nancy B Davis; Michael R Harrison; Elizabeth G Kaiser; Renee K McAlister; Kerry R Schaffer; Deborah E Wallace; Daniel J George; W Kimryn Rathmell; Brian I Rini; Tian Zhang Journal: Cancers (Basel) Date: 2022-08-07 Impact factor: 6.575
Authors: Yanlin Li; Xiaohui Jia; Yonghao Du; Ziyang Mao; Yajuan Zhang; Yuan Shen; Hong Sun; Mengjie Liu; Gang Niu; Jun Wang; Jie Hu; Min Jiao; Hui Guo Journal: Front Oncol Date: 2022-08-12 Impact factor: 5.738